cdmo means contract research, development and production organization, referring to customization, research and development and production in the medical field, is a newly emerged R&D outsourcing model in the medical field.
It is the deep docking with enterprises in all aspects, from preclinical research to clinical trials, and ultimately listed on the commercialization of production and sales, for enterprises to bring a larger scale of the production process and services, process research and development has also brought a lot of innovation for the enterprise. cdmo is in the process of the development of cra and cro was bred out of a new type of outsourcing model in the rapid development of science and technology and regulations are getting better and better. In the rapid development of science and technology and regulations more and more perfect time, relying solely on the ability of a medical enterprise has been difficult to the product from research and development to production and then listed on the independent completion.
The process is too cumbersome and difficult, and this outsourcing model just to solve the enterprise's problems, the core of this outsourcing model is to effectively help enterprises to realize the transformation of technology, shorten the time to market the product research and development, and promote sales. Enable enterprises to focus more on other areas of development, this model not only eliminates some of the risks that enterprises may bear, but also more in line with the development of today's times.
cdmo plate concept stocks
1, Boateng shares: 2020 net profit rose 74, 84% year-on-year, the company in 2015, began to provide customized R & D and production services for the Gilead Sciences research and development of antiviral drugs Remdesivir, in February 2020, the company has received Gilead Sciences formal business inquiry regarding the relevant antiviral drug intermediates.
2, WuXi AppTec: 2020 net profit year-on-year growth of 59, 62%, preclinical CRO/CDMO enterprise leader. In the global synthetic chemistry market share of more than 25%, the main business for global customers to provide small molecule chemical drug discovery, research and development and production of a full range of integrated platform services.
3, Puro Pharmaceuticals: 2020 net profit year-on-year growth of 47, 58%, May 22, 2018 announcement, the company intends to invest in the Hangzhou Economic and Technological Development Zone, Pharmaceutical Harbor Town, the construction of an independent legal person R & D center Hangzhou Yushengmet Pharmaceutical Research Institute Co.